Form 4: Avalo Therapeutics Director Gilla Kaplan Acquires Stock Options and Restricted Stock Units

Director Gilla Kaplan of Avalo Therapeutics acquired stock options and restricted stock units on August 13, 2024, according to a Form 4 filing.

Summary

• Gilla Kaplan, a director of Avalo Therapeutics, acquired stock options and restricted stock units on August 13, 2024.
• The stock options grant the right to buy 24,600 shares of common stock at an exercise price of $9.88.
• These options vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent upon continued service.
• Kaplan also acquired 9,500 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock upon vesting.
• The RSUs also vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, subject to continued service.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction of stock options and RSUs, suggesting a neutral to slightly positive sentiment as it indicates director's continued involvement with the company.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedule of the stock options and RSUs incentivizes the director to remain with the company and contribute to its long-term success.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry to attract and retain talent.
• Companies like Amgen, Gilead Sciences, and Biogen commonly use similar equity-based compensation strategies.
• The vesting schedules are typical, designed to incentivize long-term commitment and performance.

Stakeholder Impact

• The granting of stock options and RSUs can positively impact shareholders by aligning management's interests with the company's long-term success.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates